Quartz 4

Lecture and Workshop LOs

52 min read

How to read this sheet

Each objective is a broad competency statement followed on the same line by an italicised split: High-yield = the specific facts, numbers, and named classifications most likely tested in exams or critical in clinic; Lower = background, niche, or contextual detail. Bold inside a High-yield list flags the single highest-yield point of that objective.

Oral Surgery — Lecture & Workshop Learning Objectives

L1: Introduction to Practical Oral Surgery

  • Identify which patients are eligible for the student extraction clinic and which must be referred, applying the absolute exclusion criteria (impacted teeth, sedation requirement, antibiotic cover, prior head-and-neck radiotherapy, anti-resorptive agents, immunosuppressants) and the referral pathways for ineligible patients (Titanium waitlist → Oral Surgery / urgent in-person to E Block; PCOS cases via Vantage Rego electronic referral). High-yield: dual antiplatelet or dual anticoagulant therapy is an absolute exclusion; single antiplatelet or single NOAC is acceptable; warfarin requires INR ≤4.0 (preferably ≤3.5) checked within 24 h and result brought to appointment; maximum 3 teeth per session (root fragments may exceed this with tutor approval); no impacted teeth or ectopic canines/inverted wisdom teeth. Lower: institution-specific Titanium workflow steps, session capacity (2 patients per chair, 1 h 45 min appointments), bridge sectioning must be completed before the extraction session.

  • Assess radiographic and clinical complexity factors that increase extraction difficulty or risk of complications, distinguishing tooth-related from patient-related variables, and use this assessment to decide whether student-clinic management is appropriate or tutor consultation / specialist referral is required. High-yield: tooth factors — obliterated PDL space (ankylosis), apical bulbosity (hypercementosis), severe dilaceration, brittle endodontically-treated crowns, extensive caries, multi-rooted divergent anatomy; patient factors — inability to be positioned (severe kyphosis), inability to tolerate prolonged treatment, behavioural risk; radiographic approach — trace PDL space apically on every pre-operative film. Lower: mathematical bone-density indices, detailed histological mechanisms of hypercementosis.

  • Construct valid informed consent for minor oral surgery that is voluntary, informed, and specific, covering generic surgical risks and procedure-tailored risks for the relevant anatomy, and explain why pre-operative warning about adjacent-structure damage prevents the appearance of excuse-making if damage occurs. High-yield: generic risks — bleeding, bruising, swelling, pain, infection; procedure-specific — oro-antral communication (upper posterior teeth), IAN/lingual nerve injury (lower molars), dry socket, jaw fracture, adjacent tooth or restoration damage; anticoagulated patients require explicit warning about exaggerated oozing and bruising. Lower: exact scripted phrasing templates, detailed legal definitions of “material risk” under Australian Commission standards.

  • Calculate maximum local anaesthetic (LA) doses by patient weight, convert to carpule numbers for the agents used in Australian oral surgery, and decide between agents and delivery strategies for high-volume cases such as clearances or treatment of small/frail patients. High-yield: lidocaine 2% — 7 mg/kg, 44 mg per 2.2 mL carpule, max ~11 carpules at 75 kg; articaine 4% — 7 mg/kg, 88 mg per 2.2 mL carpule, max ~5.7 carpules at 75 kg; bupivacaine 0.5% — 2 mg/kg; mepivacaine 3% — adult max ~3 carpules; for multi-quadrant clearances prefer lidocaine over articaine to preserve “wiggle room” and phase treatment by quadrant; absolute ceiling 500 mg for lidocaine and articaine regardless of weight. Lower: vasoconstrictor pharmacokinetics, specific adrenaline content per carpule, jurisdictional mepivacaine mg/kg revisions.

  • Identify the nerve blocks required to achieve complete anaesthesia for any given extraction, explain why circumferential coverage (tooth, alveolar bone, palatal/lingual gingiva) is mandatory, and troubleshoot inadequate anaesthesia intra-operatively using a systematic framework. High-yield: tooth 38 = IAN block (includes lingual nerve) + long buccal nerve block; forgetting palatal or lingual infiltration is the most common cause of pain despite apparent lip numbness; IANB failure rate ~15–20%; troubleshooting hierarchy — technique miss, inflamed/infected tissue (low pH reduces LA efficacy), accessory innervation (mylohyoid supplementation for lower first molars, 0.5 carpule lingual to the tooth); distinguish pressure from pain for the patient. Lower: gate control theory of pain, detailed pH–pKa dissociation chemistry, bupivacaine kinetics in infected tissue.

  • Apply the core philosophy of exodontia (“make the hole bigger or the tooth smaller, with minimal trauma”) by selecting the appropriate strategy for simple vs complex cases, and explain the three mechanical principles underlying safe instrument use. High-yield: simple exodontia — forceps expand the socket (hole bigger); complex — bone removal or tooth sectioning (tooth smaller); lever/fulcrum — elevator on alveolar crest lifts root; wedge — luxator/elevator tip dilates PDL space; wheel-and-axle — Cryer elevator rotation for retained roots with adjacent empty socket; never use an adjacent tooth as a fulcrum. Lower: mathematical force-ratio calculations, detailed biomechanics of the Warwick James elevator.

  • Identify upper and lower dental forceps by number and tooth target, describe the anatomical design features that distinguish them, and apply safe instrument-selection and application principles to reduce the risk of crown fracture, soft-tissue injury, and adjacent-tooth damage. High-yield: upper — No. 1 (anterior straight), No. 150/150S (universal/premolar), No. 53R/53L (maxillary molars; pointed “horn” beak goes buccal into furcation), bayonet (upper 8s); lower — No. 151 (universal lower), No. 17 (lower molars, intact crown), No. 23 cowhorn (lower molars with accessible furcation); luxator (thin blade, severs PDL, no adjacent-tooth contact) vs Coupland chisel/elevator (broader tip, rotates/lifts); pointed beak always toward buccal. Lower: left-handed forceps variants, detailed beak-geometry angles, handle ergonomic variations.

  • Describe correct operator and patient positioning for maxillary and mandibular extractions, explain the critical role of non-dominant-hand support of the mandible and alveolar process, and outline safe luxation technique for beginners to minimise instrument-slip injuries. High-yield: maxillary — head tipped ~30° up, occlusal plane at operator elbow height; mandibular — occlusal plane parallel to floor; non-dominant hand must stabilise the free-floating mandible to prevent TMJ strain; never luxate palatally/lingually as a beginner (palatal artery / floor-of-mouth risk); extend index finger down the shank for grip control when learning. Lower: specific chair-angle degrees per tooth, left-handed operator positioning, loupes use considerations.

  • Conduct a systematic post-extraction assessment of the tooth and socket, deliver evidence-based post-operative instructions, and recognise and manage a vasovagal episode and other common in-clinic emergencies. High-yield: socket check — root apices intact, OAC, soft-tissue trauma, loose bone, retained fragments, haemostasis; gauze bite 20 min (30–45 min if anticoagulated); no rinsing day 1, warm salt water from day 2; paracetamol ± ibuprofen prophylactically; pain peaking at 3–5 days then worsening = dry socket or infection; vasovagal management — chair flat (head below heart), protect, summon tutor, sugary drink on recovery; smoking avoidance reduces dry socket risk. Lower: documentation of vasovagal incidents, specific electrolyte product brands.

  • Complete the Dental Surgery Safety Checklist (sign-in patient identity → time-out → sign-out) at the correct moment in the appointment rather than retrospectively, and explain the mandatory hand-hygiene and documentation requirements for the student extraction clinic. High-yield: time-out requires verbal identity confirmation (name, address, DOB), procedure confirmation, consent + allergy check, radiograph and instrument readiness; completing retrospectively risks wrong-tooth extraction; student and tutor signatures required. Lower: specific eForms/Titanium navigation, hand-hygiene certification process, exact identity script wording.

L2: Odontogenic Infection, Pain Control and Prescribing

  • Define an odontogenic infection (originating from the tooth or its supporting structures), list common causes (caries, failed endodontic therapy, pericoronitis, periodontal disease, trauma), and recognise the spectrum encompassing periapical abscess, periodontal abscess, cellulitis, osteomyelitis, odontogenic sinusitis, and Ludwig’s angina. High-yield: caries and pericoronitis as the dominant causes; periapical abscesses are predominantly anaerobic; key pathogens = Streptococcus viridans, Streptococcus anginosus, Prevotella spp., Fusobacterium spp. Lower: prevalence statistics, odontogenic sinusitis mechanism, specific microbial virulence factors.

  • Apply the SOCRATES framework to take a structured pain history (Site, Onset, Character, Radiation, Associated symptoms, Timing, Exacerbating/relieving factors, Severity), using findings to generate differentials including reversible vs irreversible pulpitis, salivary-gland pathology, tonsillar infection, and referred pain, while simultaneously assessing for visible asymmetry, dysphagia, and patient distress. High-yield: SOCRATES as a complete, examinable framework; reversible vs irreversible pulpitis distinction; dysphagia and restricted mouth opening as red-flag associated symptoms. Lower: individual mnemonic letter detail, salivary gland anatomy.

  • Recognise the classical signs of inflammation (Celsus: rubor, tumor, dolor, calor), distinguish local signs of bacterial infection (erythema, swelling, pain, heat, purulence) from systemic signs (elevated HR/RR/BP, pyrexia, malaise, rigors, confusion), and understand that spread occurs through fascial spaces and tissue planes, lymphatics, and the bloodstream — potentially causing airway obstruction, intracranial spread, or septicaemia. High-yield: local vs systemic sign list; routes of spread — fascial planes > lymphatics > blood; life-threatening complications triad. Lower: Celsus historical attribution, detailed lymphatic drainage anatomy.

  • Map the named fascial spaces to their source teeth and clinical presentations, applying the mylohyoid line rule to predict spread direction: apices above the mylohyoid line (anteriors, premolars, 1st molars) → sublingual space; apices below (2nd and 3rd molars) → submandibular space; and recognise that the infratemporal space (upper 3rd molar source) connects via the pterygoid plexus to the cavernous sinus. High-yield: mylohyoid line rule (cleanly testable, high discrimination); mandibular molar → submandibular/sublingual/pterygomandibular linkage; lateral pharyngeal four signs (trismus, jaw induration, fever, pharyngeal bulging); infratemporal → cavernous sinus pathway. Lower: individual boundary descriptions of each space, specific neurovascular contents.

  • Score fascial space infection severity using the 4-tier system (1 low: vestibular/buccal; 2 moderate: submandibular/sublingual/pterygomandibular/temporal; 3 high: lateral pharyngeal/retropharyngeal/pretracheal; 4 extreme: danger space/mediastinum/intracranial) and stage infection through inoculation (0–3 days, aerobic, soft/doughy), cellulitis (3–7 days, mixed flora, hard/exquisitely tender), and abscess (>5 days, anaerobic, fluctuant). High-yield: 3-stage table (duration, palpation, predominant bacteria — classic MCQ); severity score tier-to-space mapping, especially scores 3–4 as surgical emergencies. Lower: exact tissue-fluid composition at each stage, secondary scoring variants.

  • Recognise Ludwig’s angina as bilateral cellulitis of the submandibular and sublingual spaces (firm/brawny, often without frank pus), most commonly from mandibular 3rd molars, presenting with pyrexia, dyspnoea, dysphagia, elevated tongue and life-threatening airway compromise; and recognise cavernous sinus thrombosis as spread via the pterygoid plexus or angular/ophthalmic veins, presenting with fever, severe peri-orbital pain, exophthalmos, ophthalmoplegia, ptosis, and chemosis. High-yield: Ludwig’s angina definition (bilateral submandibular + sublingual cellulitis, airway emergency); mandibular molar as most common source; cavernous sinus thrombosis ocular signs. Lower: serosanguinous phlegmon distinction, detailed venous drainage of the cavernous sinus.

  • Diagnose SIRS (≥2 of: temp <36 °C or >38 °C; HR >90 bpm; RR >20 or PaCO₂ <32 mmHg; WCC >12,000/µL, <4,000/µL, or >10% bands) and apply qSOFA (≥2 of: SBP ≤100 mmHg; RR ≥22; GCS <15) to stratify severity, understanding that sepsis is SIRS arising from confirmed infection — life-threatening organ dysfunction from a dysregulated host response. High-yield: SIRS numerical criteria; qSOFA three components and thresholds; distinction between SIRS and sepsis. Lower: full Sepsis-3 SOFA scoring, multiorgan failure cascades (endothelial dysfunction, DIC).

  • Discuss the indications and contraindications for antibiotic prescribing in odontogenic infection, applying antibiotic stewardship: prescribe only for spreading infection, systemic involvement, or immunocompromise — not for localised drainable abscesses where surgical source control (extraction or incision and drainage) is the primary intervention. High-yield: spreading infection / systemic involvement / immunocompromise as the three triggers; avoiding antibiotics for a localised abscess that drains; Australian guidelines favour narrow-spectrum first. Lower: pharmacokinetic rationale per drug class, resistance mechanism detail.

  • Construct a basic dental formulary covering antibiotics (amoxicillin 500 mg TDS 5/7; phenoxymethylpenicillin 500 mg QDS 5/7; metronidazole 400 mg BD 5/7; clindamycin 300 mg TDS as penicillin-allergy alternative; amoxicillin-clavulanate as third-line) and antifungals (miconazole gel, nystatin). High-yield: amoxicillin and metronidazole as the two most prescribed dental antibiotics; clindamycin as the penicillin-allergy substitute; metronidazole dose; amoxicillin-clavulanate reserved third-line under stewardship. Lower: cefalexin/doxycycline indications, antifungal brand specifics.

  • Apply a stepped analgesic approach to acute dental pain — paracetamol 500–1000 mg up to QDS (max 4000 mg/day) and/or ibuprofen 400 mg 6–8 hourly (max 1200 mg/day OTC) as first-line, escalating cautiously to weak opioids (tramadol, codeine combinations) — and explain pain theories (gate control, peripheral and central sensitisation) as the conceptual basis for multimodal analgesia. High-yield: paracetamol + ibuprofen combination is superior to opioid-containing regimens for acute dental pain; max daily doses; aspirin contraindicated <16 yr (Reye’s syndrome); codeine ineffective in poor CYP2D6 metabolisers. Lower: gate control mechanistic detail, comparative opioid pharmacology, naproxen/celecoxib specifics.

L3: Wisdom Teeth

  • Describe the anatomical and developmental basis of third molar impaction, including the eruption timeline (germ appears 4–5 yr, crown mineralisation 7–10 yr, crown complete 12–16 yr, eruption 17–25 yr) and the predisposing factors of last-to-develop position, lack of retromolar space, positional irregularity, and dense posterior mandibular bone. High-yield: developmental timeline as a sequence (commonly-asked background), dense posterior mandibular bone as the primary mechanical barrier. Lower: comparative bone-density analogies, evolutionary hypotheses for impaction.

  • Recognise and pattern-match the clinical presentation of impacted third molars, including localised or vague pain, earache (particularly upper third molars), trismus, halitosis indicating chronic infection, swelling with possible eruption cysts, and the diagnostic pitfall that intraoral examination may reveal no visible pathology despite radiographic impaction. High-yield: pericoronitis as the most common associated pathology, trismus mechanism, earache association with maxillary third molars. Lower: pain radiation to temple/floor of mouth, specific swelling subtypes.

  • Classify mandibular third molar impactions using Winter’s classification (inclination vs the long axis of the second molar: vertical, mesioangular, horizontal, distoangular, transverse, inverted) and Pell & Gregory’s classification (depth Level A/B/C; ramus space Class 1/2/3), explaining how these systems together estimate surgical difficulty. High-yield: Winter’s as the most widely used; mesioangular is the most prevalent angulation (~42%); Pell & Gregory Level/Class definitions; Class 3 = embedded in ramus. Lower: precise degree ranges per Winter’s category, research-standardisation use of Pell & Gregory.

  • Apply Archer’s classification to maxillary third molars, combining angulation (1–7) with depth (a–e relative to the second molar crown and root), recognising that A7E represents far greater surgical difficulty than A1A. High-yield: Archer’s as the maxillary equivalent of Winter’s + Pell & Gregory combined; depth categories tied to second molar landmarks. Lower: Archer’s tested less than Winter’s, specific numeric angulation ranges.

  • Interpret the seven OPG signs of inferior alveolar nerve (IAN) proximity — darkening of the root, interruption of the corticated canal line, diversion of the canal, dark and bifid apex, deflection of roots, narrowing of the canal, narrowing of the roots — plus the rare but prognostic juxta-apical area, and apply these findings to consent decisions and CBCT referral thresholds. High-yield: interruption of the corticated white line and darkening of roots are the two most significant signs; juxta-apical area as rarest but most prognostic; signs prompt CBCT referral. Lower: radiographic prevalence percentages per sign, CBCT acquisition protocols.

  • Quote and contextualise IAN and lingual nerve injury risks for informed consent (temporary paraesthesia 0.5–5%, permanent <1%), explain lingual nerve injury mechanisms (direct sectioning during tooth division, lingual plate perforation, suturing within 2 mm of the crest, retraction stretch), and outline the controversy over lingual flap retraction. High-yield: temporary 0.5–5% and permanent <1% as the consent numbers; the four lingual nerve injury mechanisms; retraction controversy as a viva favourite. Lower: nerve diameter measurements, recovery neurophysiology beyond the 6–8 wk spontaneous-resolution window.

  • Diagnose and manage pericoronitis (inflammation beneath the operculum of a partially erupted tooth) using a stepwise approach — irrigate with warm saline, prescribe antibiotics only if infection is spreading, consider extracting the opposing maxillary third molar as a precipitating trauma source, and plan definitive removal — recognising that operculectomy provides only short-term relief. High-yield: pericoronitis as the most common indication for removal; warm-saline irrigation first-line; antibiotics conditional on spread; opposing-tooth extraction as an underappreciated step. Lower: specific irrigant volumes, long-term operculectomy outcomes.

  • State the indications for third molar removal (ongoing pain, single severe or recurrent infection, non-restorable caries, dentigerous cyst or tumour, root resorption of the second molar, surgical-field clearance, orthodontic plan, patient preference) and list pathologies associated with retained third molars (pericoronitis, periodontitis, caries, dentigerous cyst, OKC, ameloblastoma, SCC, external resorption of the second molar, deep space infection). High-yield: the indication list as a perennial consent/justification question; dentigerous cyst as the most common associated cyst; OKC and ameloblastoma as named tumour associations. Lower: rare metastatic lesions, precise epidemiology of individual pathologies.

  • Outline the surgical sequence for mandibular third molar removal — Flap → Trough → Section → Elevate → Irrigate → Close — with rationale for each step, and compare it against coronectomy (section 2–4 mm below the CEJ, remove all enamel, leave the root 3–4 mm below the alveolar crest, do not mobilise) and active surveillance (periodontal monitoring, OPG every 5 yr unless symptomatic). High-yield: the six-step sequence; coronectomy enamel-removal rationale and the do-not-mobilise rule; surveillance interval. Lower: suture material selection, detailed flap-design geometry.

  • Identify and manage complications of third molar surgery: IAN/lingual nerve injury, dry socket, periodontal/bony defect distal to the second molar, root or tooth displacement (lingual plate loss → submandibular space; upper third molar → pterygopalatine fossa), maxillary tuberosity fracture, oroantral communication (predict from OPG: no overlap = safe; root darkening over sinus = intimate; broken cortical sinus floor = high risk), and rare mandibular fracture. High-yield: OAC prediction from three OPG features; lingual/submandibular displacement as most-tested intra-operative complication; maxillary tuberosity fracture mechanism. Lower: retained-root acceptability threshold (<2–3 mm), extraoral retrieval technique for submandibular root loss.

L4: Oral Premalignant Disorders and Oral Cancer

  • Describe an oral lesion systematically using the eight-domain vocabulary (location; distribution/definition; size measured by periodontal probe; shape — macule/papule/nodule/plaque/vesicle/pustule/sessile/pedunculated/ulcer/erosion; colour — homogeneous vs non-homogeneous; erythro- vs leukoplakia; consistency — soft/hard/fluctuant; texture; history), and explain why systematic description is essential when clinical photographs are unavailable. High-yield: the eight-domain framework as the scaffold for viva and written lesion-description questions; key shape terms (ulcer vs erosion, sessile vs pedunculated) and colour terms (erythroplakia as higher-risk). Lower: exhaustive anatomical landmark lists, probe-technique minutiae.

  • Apply a structured surgical sieve — VITAMINS CDE or ACTIVE MINDS — consistently to any oral mucosal lesion to generate a complete differential diagnosis, selecting one sieve and applying it without omitting categories. High-yield: knowing both mnemonics; the principle that consistent category-by-category application earns marks even when the diagnosis is uncertain; linking categories to examples (betel nut → submucous fibrosis, calcium channel blockers → gingival overgrowth). Lower: full example list within every category, source citation detail.

  • Recognise the clinical red-flag features that should trigger urgent specialist referral: persistent red/white mucosal lesions, ulceration, induration (rock-hard on palpation despite soft appearance), fixation to deep tissue, rapid unexplained growth, spontaneous bleeding without periodontal cause, unexplained numbness/paraesthesia, trismus without obvious cause, and palpable cervical lymphadenopathy. High-yield: the complete red-flag list — any single item triggers urgency; induration and unexplained numbness are the most clinically underappreciated. Lower: specific case vignettes, distinguishing mealtime salivary swelling from rapid growth.

  • Place oral epithelial dysplasia on the WHO grading continuum (mild — outer third; moderate — middle third; severe — beyond two thirds; carcinoma in situ — full-thickness without basement-membrane invasion; carcinoma — invasion through the basement membrane), and apply the WHO 2017 update that merged severe dysplasia and carcinoma in situ, noting the importance of identifying which system the literature uses. High-yield: the five-step continuum with structural definitions; the 2017 simplification (severe + CIS = one category) as an exam trap; any severe dysplasia mandates urgent action. Lower: comparative table of parallel systems (SIN, Ljubljana, SIL, Binary), inter-rater variability data.

  • Recall and rank malignant transformation rates for oral potentially malignant disorders (OPMDs): lichen planus 1.4%, lichenoid lesions 3.8%, leukoplakia 8.6%, oral submucous fibrosis 5.2%, erythroplakia ~33%, proliferative verrucous leukoplakia (PVL) ~50%, and explain that PVL cannot be distinguished from standard leukoplakia on appearance alone, mandating biopsy and three-monthly surveillance. High-yield: the six transformation rates in rank order — PVL ~50% and erythroplakia ~33% are the exam favourites; leukoplakia 8.6% as the most commonly encountered OPMD; lichen planus 1.4%. Lower: study-level variation, confidence intervals, erosive vs reticular lichen planus sub-rates.

  • Identify the anatomically high-risk sites for oral malignancy (lateral and ventral tongue, floor of mouth, retromolar pad, soft palate complex) and explain that lesions at these sites warrant a lower biopsy threshold and more urgent referral even without other red flags. High-yield: the four high-risk site groups — lateral/ventral tongue and floor of mouth are the highest-yield pair; tobacco/alcohol association; erythroplakia at these sites is malignant until proven otherwise. Lower: sub-site incidence data, molecular carcinogenesis mechanisms.

  • Triage referral urgency: suspected malignancy = urgent (seen within a maximum of 2 weeks); suspected pre-malignancy may also be urgent because transformation may already have occurred; default to an urgent referral when uncertain after seeking a second opinion or calling the specialist. High-yield: the 2-week rule for suspected malignancy; pre-malignancy can also warrant urgent classification; default-to-urgent when uncertain. Lower: specific triage personnel, exact OHCWA referral-form fields.

  • Compose a professional referral letter including practitioner and patient details, relevant medical history, a systematic lesion description, clinical photographs, differential diagnoses, a clearly stated objective, and explicit urgency, and differentiate the public (OHCWA form) from private referral pathways. High-yield: the seven components of a complete referral; urgency as the single most critical field in both pathways; systematic lesion description as the content that most differentiates a useful referral. Lower: private clinic addresses and digital-form fields, institution-specific clinic codes.

  • Plan pre-radiotherapy dental clearance: assess caries and apical pathology, obtain OPG + full-mouth periapical series + bitewings, extract all hopeless teeth and teeth with apical pathology in the radiation field before RT, allow ideally ≥2 weeks (preferably 4–6 weeks) healing before RT commences, and prescribe high-fluoride toothpaste (Neutrafluor 5000). High-yield: the rationale that post-RT extraction in irradiated bone carries high ORN risk, so clearance must occur pre-RT; the ≥2-week (ideally 4–6-week) window; OPG + full PA series + BWs as the minimum imaging set. Lower: radiographic criteria for “hopeless”, dose-zone thresholds (see W2.2).

  • Manage post-treatment head and neck cancer patients in general practice across four domains — mucositis (Difflam benzydamine 50/50 rinse), xerostomia (Biotene products, saliva substitutes), caries prevention (Neutrafluor 5000, silver diamine fluoride), and long-term surveillance (lifelong shared-care review, candidiasis screening, ORN risk framing every extraction). High-yield: the four management domains as a complete recall list; named products (Difflam, Biotene, Neutrafluor 5000, SDF); lifelong surveillance and ORN risk as the core principles. Lower: exact dilution ratios, individual Biotene formulation specifics.

L5: Anxiolysis, Sedation, and General Anaesthesia

  • Define and differentiate the four TGA/ANZCA sedation levels — minimal sedation (anxiolysis: purposeful response to verbal/light tactile stimulus, no airway intervention), moderate sedation (depressed consciousness but purposeful response retained, achieved by IV drugs or oral + inhalational combinations), deep sedation (roused only by noxious stimulus, airway maintenance often impaired), and general anaesthesia (controlled unconsciousness, loss of airway reflexes) — explaining the continuum as progressively greater CNS depression with greater airway/cardiovascular risk. High-yield: the four-level spectrum and its airway/ventilation/CVS implications per level; moderate = IV drugs OR oral + inhalational (not oral alone); GA = loss of protective reflexes. Lower: agent-specific pharmacodynamics per level, Guedel’s four historical stages as background.

  • State Australian scope-of-practice requirements for each sedation level: general dentists may provide minimal sedation only (inhalational or single oral agent) with appropriate training (6.5-h ADA CPD inhalation course); endorsed dentists may provide moderate sedation only after the Dental Board–approved two-year USyd Graduate Diploma; deep sedation and GA are restricted to anaesthetists in approved facilities. High-yield: GP dentist = minimal sedation ceiling; endorsement = 2-year USyd Grad Dip; deep/GA = anaesthetist only; N₂O alone needs no endorsement provided minimal-sedation depth is not exceeded. Lower: international qualification equivalence, facility accreditation detail.

  • Describe non-pharmacological anxiety-management strategies — communication (empathy, predictive sensory warnings, calm demeanour), environmental modification (visual/auditory/olfactory control), acupuncture and acupressure (WHO-endorsed 2003; CV-24 for gag, PC-6 for anxiety/gag), hypnosis (~8% highly suggestible; useful adjunct), and CBT (referral-based, reduces long-term avoidance) — and apply them within a tiered framework. High-yield: CV-24 and PC-6 acupoints and their indications; WHO 2003 endorsement; predictive warnings as a first-line communication tool. Lower: VR/distraction specifics, CBT referral pathways, hypnotic scripts.

  • Explain nitrous oxide (N₂O) pharmacology and its anxiolytic/analgesic mechanism — NMDA antagonism (analgesia), endogenous opioid release (analgesia), and GABA-A potentiation (anxiolysis); acts within Guedel Stage 1; low blood/gas solubility coefficient of 0.47 underlies rapid onset and recovery; not metabolised; 50% N₂O ≈ 10–15 mg morphine; non-flammable but supports combustion. High-yield: the three mechanisms (NMDA/opioid/GABA-A), blood solubility 0.47 → rapid onset/offset, not metabolised, analgesic equivalence. Lower: receptor subunit binding, comparison with other inhalational agents.

  • Explain diffusion hypoxia and its prevention: on N₂O cessation the gas rapidly moves from blood into alveoli, displacing alveolar O₂ and causing transient hypoxaemia; prevented by 100% O₂ for 2–5 minutes at the end of every N₂O procedure; children desaturate faster than adults. High-yield: mechanism plus the mandatory 100% O₂ for 2–5 min post-procedure — the single most classic N₂O safety question. Lower: quantitative SpO₂ drop data, adult vs paediatric subgroup differences.

  • Apply indications and contraindications for N₂O inhalation sedation and identify equipment safety features: indicated for fear/anxiety, pain control, gagging, and complex/traumatic procedures; contraindicated in claustrophobia, inadequate understanding, severe anxiety, upper-anterior fine-access procedures, nasal obstruction/URTI, ASA III–V, COPD, 1st-trimester pregnancy, and severe psychiatric disorders; safety features include pin-index, colour coding, O₂ flush, O₂ fail-safe, minimum 30% O₂ delivery, one-way valves, reservoir bag monitor, and active scavenging. High-yield: the contraindication list (URTI, 1st-trimester pregnancy, COPD, ASA III–V, upper-anterior access) and the O₂ fail-safe as the key safety mechanism. Lower: chronic-exposure staff risks (B12 inactivation), scavenging double-hood detail.

  • Conduct an N₂O relative analgesia session correctly: obtain written consent at a prior visit; chaperone present; start at 100% O₂ at 4–6 L/min; titrate N₂O in 5–10% increments every 1–2 min to a typical endpoint of 35–45%; peak at 5–7 min; monitor SpO₂ and reservoir bag; conclude with 100% O₂ for 5 min; escort required. High-yield: titration increments 5–10%, target 35–45%, 5–7 min to peak, written consent beforehand, 5 min 100% O₂ recovery. Lower: flow-meter indicator detail, ADA billing codes, course/cost specifics.

  • Prescribe oral benzodiazepines for minimal sedation and apply the critical scope boundary: temazepam 10 mg, lorazepam 1 mg, or diazepam 2–5 mg taken orally 1 h before the procedure at the practice; titrate upward visit-by-visit with caution in the elderly/frail; single-dose scripts only; escort required; combining any oral benzodiazepine with N₂O elevates the level to moderate sedation — outside general-dentist scope. High-yield: the three drug–dose pairs and the “benzo + N₂O = moderate sedation” scope trap; escort requirement; single-dose prescribing. Lower: deprecated lorazepam dosing, night-before dosing option, OSA/elderly caution.

  • Outline IV sedation requirements, agents, and monitoring: classified as moderate sedation; minimum three-person team; staff hold HLTAID015 advanced life support; primary agent midazolam (reversible with flumazenil — note flumazenil’s shorter half-life and rebound sedation risk); anaesthetist-led sedation adds propofol/remifentanil; monitor HR, BP, SpO₂, ideally capnography; 24-h post-sedation restrictions (no driving, heavy machinery, or legal documents). High-yield: midazolam as primary agent, three-person team, HLTAID015, flumazenil reversal with rebound caveat, 24-h restrictions. Lower: propofol/remifentanil for anaesthetist-led cases, Medicare rebate codes, induction-time variability.

  • Apply the clinical sedation decision tree (skill → LA feasible? → IV sedation suitable? → oral benzodiazepine viable? → non-pharmacological sufficient? → refer) and the Southbank Day Surgery acceptance criteria (weight <130 kg, BMI <40 — up to 42 with approval, no OSA; otherwise refer to RPH/SCGH/FSH), and outline methoxyflurane (Penthrox) use and dose limits (6 mL/day, 6 mL/week) with its limited dental role. High-yield: the decision-tree sequence, Southbank weight <130 kg and BMI <40 cut-offs, and the do-not-promise-GA-before-assessment rule. Lower: Penthrox device mechanics, public-hospital allocation by postcode, BMI sub-tier criteria.

W1: Surgical Extractions, Flaps, Complications and Management

  • Apply enhanced surgical asepsis and take a focused pre-operative medical history, distinguishing when sterile precautions are required versus a clean setup, and identifying systemic conditions that modify surgical risk. High-yield: sterile setup triggered by flap elevation or bone penetration (ADA IPC 5th ed.) vs clean setup for simple exodontia; medical screen must cover diabetes (glycaemic control, hypoglycaemia), anticoagulants (specific agents, do not modify independently), seizures/recent TIA, immunocompromise, and long-term steroids (adrenal insufficiency). Lower: detailed adrenal-crisis physiology, full ADA infection-control text.

  • Demonstrate safe sharps management throughout a surgical extraction, from LA assembly to scalpel blade mounting/dismounting and suture needle handling. High-yield: one-handed recapping using a recapping device, scalpel blades mounted/removed with needle holders away from personnel, suture needles held with tweezers until proficient. Lower: specific safe-disassembly sequences per instrument, device-counter specifics.

  • Classify wound closure intention and describe the four sequential phases of extraction socket healing with timings. High-yield: primary intention (sutured flap) favours regeneration over fibrosis; secondary intention (dehiscence/biopsy) favours fibrosis; tertiary intention (delayed primary closure) for contaminated wounds; Phase I haemostasis/coagulation 0–24 h; Phase II inflammation 24 h–1 wk (granulation); Phase III proliferation from 2 wk (fibroplasia, woven bone); Phase IV modeling/remodeling from 4 wk (lamellar bone). Lower: cytokine/growth-factor signalling within each phase.

  • Explain predictable post-extraction alveolar ridge resorption and justify socket-preservation indications. High-yield: ~3.4 mm horizontal loss, ~1.33 mm vertical buccal loss, ~0.5 mm lingual vertical loss; resorption affects future dentures, bridges, and implants; socket preservation stabilises the clot and limits dimensional loss. Lower: bone-graft material composition, remodelling timeline beyond 4 weeks.

  • List and differentiate indications for surgical extraction and select between enucleation and marsupialisation for pathological lesions. High-yield: surgical extraction for impacted/retained roots, anticipated difficult extraction (divergent/bulbous roots, ankylosis, gross caries), cyst/pathology management, and pre-prosthetic surgery; enucleation = complete removal for smaller/accessible cysts; marsupialisation = decompression to shrink large cysts and avoid massive defects near vital structures. Lower: OKC-specific marsupialisation rationale, pre-prosthetic procedures (alveolectomy, tuberosity reduction, exostosis removal) beyond named examples.

  • Design a full-thickness mucoperiosteal flap applying the principles of a broad base, perpendicular relieving incisions to bone, and papilla protection, and compare the three principal flap types by access, closure complexity, and tearing risk. High-yield: envelope (sulcular only) — simplest to close, prone to tearing if under-extended; triangular (sulcular + one relieving) — better retraction, less tearing; trapezoidal (sulcular + two relieving) — maximum access, more closure work; base wider than free margin; never bisect an interdental papilla; semilunar flap for apicoectomies/small cysts. Lower: crestal implant-flap variants, pedicled-flap geometry for OAC.

  • Apply the principles of flapless tooth sectioning (Item 314) and bone removal to facilitate extraction, selecting the correct handpiece and managing thermal risk. High-yield: Item 314 = sectional extraction; straight surgical handpiece mandatory once a flap is raised or bone is penetrated (prevents surgical emphysema); remove bone mesially/distally first, never palatally; bone necrosis at >47 °C for ≥1 min; manual saline irrigation required. Lower: bur type selection, maxillary molar root-sectioning geometry.

  • Select suture material and technique by clinical need, distinguishing resorbable from non-resorbable, monofilament from braided, and common suture patterns by indication. High-yield: Vicryl Rapide (braided, loses ~50% strength at 10–14 days) preferred for intra-oral mucosa; silk non-resorbable, falling from favour (wicks bacteria, needs removal); PTFE/Prolene low-reactivity for implant surgery; USP sizing inverse (3-0 < 1-0); simple interrupted most reliable (one failed stitch does not unravel the line); continuous economical but unravels if the knot fails. Lower: full USP/EP conversion table, detailed needle-code list.

  • Recognise, prevent, and manage the key intra- and post-operative complications of surgical extraction: bleeding, surgical emphysema, retained or displaced roots, oroantral communication, fractured tuberosity, alveolar osteitis, and wrong-tooth extraction. High-yield: OAC = breach of cortical bone and Schneiderian membrane; <2 mm managed conservatively with haemostatic agent + suture + sinus precautions; >2 mm needs surgical closure (buccal advancement/palatal rotation/Bichat’s fat pad) + OMFS referral; dry socket (clot loss + fibrinolysis) treated with irrigation + obtundent dressing, antibiotics only if spreading; surgical emphysema prevented by a surgical handpiece, self-limiting; retained root <3 mm may be left if no periapical pathology; wrong-tooth risk highest in orthodontic cases — use a correct-site checklist. Lower: haemostatic material comparisons, tranexamic acid rinse protocols, tuberosity-splinting techniques.

  • Define MRONJ using the AAOMS diagnostic triad (exposed bone, or bone probeable via an intraoral/extraoral fistula, failing to heal >8 weeks + a history of antiresorptive or antiangiogenic therapy + no prior head and neck radiation), understanding that all three criteria must be satisfied simultaneously. High-yield: the triad is the entry point of every MRONJ question — memorise each limb exactly; Stage 0 is the pre-clinical form with non-specific findings and no exposed bone; antiangiogenic agents (VEGF inhibitors, TKIs, mTOR inhibitors) qualify in addition to antiresorptives. Lower: intraoral vs extraoral fistula probing nuance, the 8-week threshold in immunocompromised patients.

  • Apply the AAOMS staging system (Stages 0–3), recognising that staging drives the choice between non-operative and operative management. High-yield: Stage 1 = asymptomatic exposed bone (CHX rinses + sequestrum removal); Stage 2 = exposed bone + infection/pain (add systemic antibiotics); Stage 3 = Stage 2 plus pathologic fracture, extraoral fistula, oro-antral/oro-nasal communication, or lytic extension to the inferior border/sinus floor (consider operative therapy). Lower: precise mandibular vs maxillary operative sub-protocols (marginal resection, alveolectomy, segmental resection + free flap for defects >2.5 cm).

  • Compare the pharmacology of bisphosphonates and denosumab (mechanism, half-life, reversibility, and implications for risk and timing) and explain the RANKL/OPG axis governing osteoclast activity. High-yield: bisphosphonates bind hydroxyapatite, half-life ~10 years (alendronate) — effects persist after cessation; nitrogen-containing types (zoledronic acid, alendronate, pamidronate) more potent; denosumab is an anti-RANKL monoclonal with ~30-day half-life, reversible within ~6 months as it does not bind bone; osteoblasts secrete RANKL and OPG to balance resorption; denosumab mimics OPG; timing extractions 3–4 months after the last denosumab dose reduces risk. Lower: non-nitrogen bisphosphonate mechanism, sclerostin/romosozumab biology.

  • Describe the five MRONJ pathophysiology hypotheses in order of likelihood — bone remodelling inhibition (leading), infection/inflammation, angiogenesis inhibition, immune dysfunction, and genetic factors — and explain how each contributes to failed jaw healing after dentoalveolar trauma. High-yield: bone remodelling inhibition as the leading hypothesis (osteoclast suppression prevents micro-repair after extraction); infection/inflammation second; ranking is examinable. Lower: experimental MSC infusion, animal-model osteoclast data, candidate gene SNPs.

  • Stratify patient MRONJ risk by indication, drug class, and route, and identify additive local and systemic risk factors. High-yield: oncology IV bisphosphonate/denosumab risk is highest (~1–5%, up to ~18% with prolonged therapy); osteoporosis oral bisphosphonate risk is very low (~0.02–0.05%); tooth extraction is the commonest precipitating local factor; mandible affected ~75% vs maxilla ~25%; comorbidities (corticosteroids, diabetes, RA, smoking, poor OH) amplify risk. Lower: duration-of-therapy gradient detail, non-malignant denosumab indications, romosozumab risk figures.

  • Plan dental management across the three time periods relative to therapy — before initiation, during therapy, and when an established lesion is present — applying the principle that prevention outweighs treatment. High-yield: before — multidisciplinary dental clearance, extract poor-prognosis teeth, allow healing before therapy; during — atraumatic technique, primary closure, CHX, antibiotic cover for high-risk extractions, avoid elective implants; established — do not abandon the patient, refer to OMFS, non-operative care for Stages 1–2, operative for Stage 3 or non-resolving Stage 2. Lower: avoiding compromise of oncologic/fracture-prevention therapy, CTX bone-turnover marker (regional, not universally validated).

  • Evaluate the drug-holiday concept, including its rationale and the key differences between bisphosphonates and denosumab. High-yield: a bisphosphonate drug holiday is not proven to reduce MRONJ risk and is generally not recommended (10-year bone half-life); denosumab cessation risks rebound vertebral fractures and hypercalcaemia, so any holiday must be coordinated with the prescriber and timed around dosing; the decision rests with the prescribing physician, not the dentist alone. Lower: lack of a validated biomarker accepted by AAOMS for individual decisions.

  • Recognise romosozumab (sclerostin inhibitor) as a newer dual-action bone agent with emerging MRONJ-relevant pharmacology, requiring the same risk-conscious approach despite a low osteoporosis MRONJ rate (~0.03–0.05%). High-yield: osteocytes produce sclerostin (inhibits osteoblasts); romosozumab neutralises it to densify bone while also reducing resorption — a unique dual mechanism; MRONJ risk low but not zero. Lower: monthly SC dosing for 12 months, cardiovascular safety signal, investigational oncology indications.

W2.2: Osteoradionecrosis

  • Define osteoradionecrosis (ORN) using the ISOO–MASCC–ASCO criteria — a radiographic lytic/mixed sclerotic bone lesion AND/OR visibly exposed bone or bone probed through a pocket or fistula, occurring in a site previously exposed to therapeutic head and neck radiation — and state the key risk threshold. High-yield: ≥50 Gy to the jaw is the defined risk threshold; risk is lifelong and increases with time post-RT (not static or reversible); modifiable amplifiers include poor oral hygiene, dentoalveolar surgery, and tobacco. Lower: ORN also occurs in thorax and long bones; ascertain the specific cancer, dose, and exact field when RT history is present.

  • Explain ORN pathophysiology through the “3 Hs” — hypovascularity, hypocellularity, and hypoxia — produced by radiation-induced vascular damage and tissue fibrosis, and contrast it with MRONJ (no RT history by definition) to avoid diagnostic confusion. High-yield: the 3 Hs explain impaired healing and accumulating risk over decades; radiation-induced fibrosis underpins the rationale for pentoxifylline and tocopherol. Lower: reactive oxygen species and TNF-α cascade detail, myofibroblast expression.

  • Apply the ClinRad staging system (Grade 0–4) to classify ORN severity and guide intervention, and explain why it is preferred over the legacy Notani classification. High-yield: Grade 0 = superficial mobile sequestra only; Grade 1 = radiographic necrosis confined to alveolar bone, intact mucosa (no intervention); Grade 2 = exposed bone → minor surgery ± medical management; Grade 3 = basilar/sinus involvement → intermediate transoral surgery; Grade 4 = pathologic fracture/orocutaneous fistula/oro-antral communication → segmental resection + vascularised free flap. Lower: ClinRad’s superior inter-rater reliability vs Notani/LENT-SOMA/Store.

  • Implement pre-radiotherapy (pre-RT) dental prevention, including radiation-field optimisation, dental clearance, extraction sequencing, and remineralisation. High-yield: use IMRT to limit jaw dose <50 Gy; extract hopeless, periapical, and moderate–severe periodontal teeth in the field; allow ≥2 weeks (preferably 4–6 weeks) healing before RT; complete extractions that alter vertical dimension before mask fabrication; prescribe high-fluoride toothpaste. Lower: endodontic retreatment vs extraction decision-making for borderline teeth.

  • Implement post-radiotherapy (post-RT) prevention for any planned dentoalveolar procedure, integrating field-map review, a surgical-avoidance hierarchy, decoronation, antibiotic prophylaxis, and PENTOCLO. High-yield: always review radiation field maps before surgery; avoid extraction/implants in high-risk irradiated zones; PENTOCLO = pentoxifylline 400 mg BD + tocopherol 1000 IU from 1 week pre- to ≥4 weeks post-extraction; antibiotics 1 day pre + 7 days post + chlorhexidine. Lower: decoronation (root burial with RCT) for compromised teeth where extraction is prohibitive.

  • Recognise that prophylactic hyperbaric oxygen therapy (HBOT) is no longer routinely recommended by the ISOO–MASCC–ASCO guideline, understand the evidence basis, and identify the limited context where it may still be considered. High-yield: RCT/systematic-review evidence does not support routine prophylactic HBOT before extractions; HBOT monotherapy success is low (~38%) and only improves when combined with surgery; guideline position is “not recommended for routine use.” Lower: HBOT as a surgical adjunct in selected cancer-free early-ORN cases, minimal photobiomodulation evidence.

  • Describe the PENTOCLO mechanism, dosing, and role in both prevention and non-surgical treatment of established ORN, and outline how it targets radiation-induced fibrosis. High-yield: pentoxifylline 400 mg BD (vasodilator, improves RBC deformability, anti-fibrotic via TNF-α inhibition) + tocopherol 1000 IU (free-radical scavenger) = PENTO for prevention/early ORN; full PENTOCLO adds clodronate for refractory/severe disease; inexpensive, safe, increasingly preferred over HBOT. Lower: Delanian et al. trial data and the wide variation in reported healing rates.

  • Apply a stage-matched surgical management algorithm for established ORN, from conservative sequestrectomy to radical resection with vascularised reconstruction. High-yield: ClinRad 2 → sequestrectomy ± medical therapy; ClinRad 3 → transoral debridement/alveolectomy; ClinRad 4 (pathologic fracture, fistula, communication, or lesion >2.5 cm) → segmental resection + vascularised free flap (fibula preferred; radial forearm or scapular as alternatives). Lower: MDT consideration of patient fitness/support for prolonged surgery, second free flap if ORN recurs in a reconstructed fibula.

  • Apply the practical pearl of verifying the actual radiation field map before assuming an extraction is high-risk, and describe the appropriate referral and communication approach for irradiated patients. High-yield: request radiation field maps before any surgical decision — a field targeting the oropharynx/skull base without jaw coverage does not confer ORN risk at extraction sites; document field review. Lower: calling a specialist registrar for acute advice in rural/non-specialist settings, building skills on healthy patients first.

W2.3: Surgical Extraction Tips and Risk Management

  • Apply a structured pre-operative assessment for every extraction — a concise patient presentation (name, age, tooth, reason) and radiograph review before any management discussion — integrating tooth mobility, crown/root condition, bone density, and proximity to nerves or sinus to decide between simple and surgical extraction. High-yield: explicitly asking about antiresorptives (bisphosphonates, denosumab/Prolia) and anticoagulants (warfarin, DOACs) because patients routinely do not volunteer these drug names — failure to identify them is the primary medico-legal pitfall; dense bone with an intact periodontium adds unexpected difficulty in older patients. Lower: formal difficulty-scoring instruments, bone-density grading systems.

  • Apply atraumatic luxation technique by engaging the periodontal ligament space at approximately 45° to the long axis (not a vertical shove), using controlled incremental sliding force apically to sever PDL fibres gradually, placing buccal and lingual/palatal finger stops to arrest instrument slippage, and resting a finger against the lingual surface to detect movement before it is visible. High-yield: ~45° entry into the PDL space; controlled sliding rather than levering; dual finger-stop placement; the sensation of gradual release as PDL fibres sever. Lower: periotome or piezoelectric atraumatic adjuncts, PDL stress-distribution models.

  • Construct procedure-specific informed consent that explicitly names the risk of root fracture and the possibility that specialist referral may be required, document the discussion before the procedure begins, and recognise that what was communicated pre-operatively is the primary record if a complication later occurs. High-yield: root fracture + referral as non-negotiable consent items for any extraction; documentation timing (before, not after, the adverse event). Lower: root-fracture incidence figures by tooth type, detailed medico-legal frameworks.

  • Decide when to stop mid-procedure and refer rather than escalate: if a root fractures beyond your retrievable skill, or the case converts from simple to surgical (flap + bone removal) in an antiresorptive patient — stop, achieve haemostasis, consider antibiotics if indicated, close the site, explain calmly, and arrange referral within days to weeks rather than as an emergency. High-yield: do not create a larger surgical defect you cannot confidently manage in an antiresorptive patient — close and refer; specialist input is rarely an emergency; avoid being pressured to proceed beyond competence. Lower: formal referral-letter writing, institution-specific waitlist pathways.

  • Choose suturing and haemostatic packing rationally: suture only to stabilise a mobile flap or to secure haemostatic material — not to “close” an already-approximated socket where it becomes a food trap; use resorbable haemostatic agents (e.g., oxidised cellulose) in high-bleeding-risk patients; and balance the foreign-body concern in antiresorptive patients against the more immediate danger of uncontrolled haemorrhage in anticoagulated patients. High-yield: suture rationale = flap stabilisation or haemostatic-agent retention, not routine socket closure; oxidised cellulose + suture as first-line in anticoagulated patients; the foreign-body vs MRONJ tension in dual-risk patients. Lower: oxidised-cellulose product comparisons, suture gauge/material selection beyond resorbable vs non-resorbable.

  • Manage post-extraction bleeding by timing and cause — immediate (soft tissue/socket: pressure, suture, haemostatic agent), delayed (haemostatic failure after the anaesthetic wears off, or infection eroding a vessel: irrigate, re-pack, re-suture, escalate), and advise all patients on signs requiring urgent review — ensuring anticoagulated patients have adequate local measures before discharge. High-yield: three bleeding timeframes — immediate, delayed haemostatic failure, infection-related — each with distinct management; local measures (gauze, oxidised cellulose, tranexamic acid rinse, suture) manage the vast majority without altering anticoagulation. Lower: tranexamic acid concentration protocols, comparative haemostatic-agent trial data.

  • Manage suspected or inadvertent MRONJ by continuing to care for the patient (not abandoning them), referring promptly to OMFS, providing supportive measures (oral hygiene, antibiotics if infected, conservative debridement only), and scheduling long-term follow-up — recognising the practitioner’s ongoing ethical obligation. High-yield: do not abandon the patient; refer OMFS; avoid aggressive surgical debridement that can worsen MRONJ — conservative management is first-line; long-term follow-up is non-negotiable. Lower: PENTOCLO protocol for established MRONJ (see W2.1), AAOMS staging applied to post-extraction scenarios.

W3.1: Salivary Gland Surgery

  • Describe the anatomy and secretory roles of the major salivary glands (parotid, submandibular, sublingual) and the minor salivary glands, and explain how each gland’s anatomical and physiological properties predispose it to specific pathologies (obstructive, inflammatory, neoplastic). High-yield: three paired major glands plus widely distributed minor glands; the submandibular gland is most prone to calculi (tortuous upward-coursing Wharton’s duct, mucous alkaline secretion); minor glands (lower lip) most prone to mucoceles. Lower: acinar cell physiology, parasympathetic vs sympathetic secretomotor pathways.

  • Explain the pathophysiology of sialolithiasis, identify the most common gland affected, and describe its clinical presentation and sequelae including ductal squamous metaplasia, microbial biofilm, and secondary inflammation and fibrosis. High-yield: 80% of salivary calculi occur in the submandibular gland; calculi form by calcium-salt deposition around an organic nidus; they trigger squamous metaplasia of the duct lining and support microbial adherence, leading to obstructive sialadenitis (“mealtime syndrome”). Lower: precise biochemical composition of calculi, genetic predispositions.

  • Compare the diagnostic imaging modalities for salivary gland disease — CT, MRI, and sialography — and state the preferred indication for each, including the technique of sialography (contrast injected into a single duct, then radiographs). High-yield: CT/MRI preferred for suspected neoplasm (MRI superior for tumour–tissue interface and predicting malignancy); sialography preferred for inflammatory/obstructive disease and stricture mapping; sialography contraindicated in acute infection. Lower: ultrasound-guided aspiration, cone-beam CT dose considerations.

  • Describe sialoendoscopy and minimally invasive stone retrieval, and outline the stepped management algorithm for submandibular obstruction from conservative measures through to gland excision. High-yield: sialoendoscopy with wire-basket retrieval is gland-preserving first-line for accessible ductal calculi; escalation — antibiotics (acute infection) → lithotripsy ± sialoendoscopy → sialolithotomy → submandibular gland excision. Lower: laser vs pneumatic lithotripsy, intracorporeal vs extracorporeal techniques.

  • Distinguish mucocele from ranula in pathogenesis, gland of origin, clinical features, and management, explaining why simple drainage is insufficient and when marsupialisation versus excision is selected. High-yield: mucocele = minor-gland mucous extravasation (commonly lower lip), treated by excision of the lesion with the underlying minor gland; ranula = sublingual-gland extravasation on the floor of mouth (soft, fluctuant, bluish), managed by marsupialisation with sublingual gland removal or excision; recurrence is the key risk if the gland is left. Lower: plunging ranula extension through mylohyoid, marsupialisation suturing detail.

  • Explain the surgical anatomy of the submandibular triangle and identify the three nerves at risk during submandibular gland excision, specifying the most commonly injured nerve and the functional deficit of each. High-yield: the marginal mandibular branch of the facial nerve is most commonly injured (lower-lip weakness/asymmetry); lingual nerve injury → ipsilateral tongue anaesthesia and loss of anterior taste; hypoglossal nerve injury → ipsilateral tongue deviation and dysarthria; key structures = Wharton’s duct, lingual nerve, hypoglossal nerve, digastric. Lower: retromandibular vein haemorrhage, cervical cutaneous branch injury.

  • Summarise the epidemiology and gland-site distribution of salivary gland neoplasms and apply the rule that malignancy risk rises as gland size falls. High-yield: parotid holds 70–85% of all tumours but only ~25–32% are malignant; submandibular ~37–45% malignant; minor glands ~45–82% malignant; sublingual ~70–90% malignant — the smaller the gland, the higher the malignant proportion; malignant lesions typically present after age 60, benign 40–60. Lower: Australian incidence figures, proportion of head and neck cancers.

  • Classify salivary gland neoplasms into benign epithelial (adenomas), malignant epithelial (carcinomas), and non-epithelial tumours, and compare benign vs malignant clinical features (growth rate, consistency, ulceration, nerve involvement, lymph node status). High-yield: pleomorphic adenoma is the commonest salivary tumour overall (~75%, predominantly parotid); Warthin’s tumour second commonest benign; mucoepidermoid carcinoma the most common malignant; adenoid cystic carcinoma notable for perineural invasion; malignant red flags = hard/fixed, painful, rapid growth, cranial-nerve palsy, ulceration, lymphadenopathy. Lower: acinic cell, polymorphous low-grade adenocarcinoma, carcinoma ex pleomorphic adenoma transformation risk.

  • Apply fine needle aspiration cytology (FNAC) as the primary pre-operative diagnostic tool for a salivary mass, interpret its parameters, and recognise its limitations in subtyping. High-yield: FNAC establishes benign vs malignant in ~82% of cases; minimally invasive, inexpensive, well tolerated; accuracy is operator-dependent; particularly unreliable for cystic lesions (Warthin’s, mucoepidermoid carcinoma) and low-grade mucoepidermoid carcinoma. Lower: Milan System reporting categories, core-needle biopsy as an alternative.

  • Describe the principles of parotidectomy with facial nerve identification and preservation, and outline the pathway for parotid malignancy (neck dissection, adjuvant radiotherapy) and prosthetic rehabilitation of palatal defects. High-yield: the facial nerve is the paramount landmark in parotidectomy — identified at its trunk using the tragal pointer and posterior belly of digastric; superficial parotidectomy dissects along the nerve plane; facial nerve injury is the most feared complication; nodal-positive malignancy needs neck dissection + adjuvant radiotherapy; palatal defects rehabilitated with an obturator. Lower: total vs superficial vs extended parotidectomy indications, Frey’s syndrome (gustatory sweating), radiotherapy dosing.

W3.2–3.3: Cysts & Aggressive Bone Lesions

Cysts of the Jaws

  • Define a jaw cyst as a pathological epithelial-lined, fluid-filled cavity, distinguish odontogenic from non-odontogenic cysts (e.g., nasopalatine duct, nasolabial), and recall the relative frequency distribution. High-yield: periapical 65–70%, dentigerous 15–18%, nasopalatine 5–10%, OKC 3–5% — “radicular” is correct ~two-thirds of the time; odontogenic vs non-odontogenic origin. Lower: lateral periodontal and paradental cysts (<1% each), nasopalatine embryology.

  • Describe the radiographic features shared by jaw cysts and apply the critical cyst-versus-tumour differentiator on imaging. High-yield: well-defined, corticated, smooth-bordered radiolucency; slow-growing; cysts displace rather than resorb adjacent teeth — aggressive tumours resorb; CBCT/CT used when cortical expansion or proximity to nerves/sinus must be assessed; diagnosis ultimately depends on histopathology. Lower: fluid-aspiration technique, imaging-protocol variations.

  • Diagnose and manage a periapical (radicular) cyst, the most common jaw cyst, and recognise its typical presentation. High-yield: rounded, well-circumscribed corticated radiolucency at the apex of a non-vital tooth; inflammatory odontogenic origin; managed by enucleation after extraction or RCT; does not recur once treated. Lower: Malassez epithelial-rest activation, granuloma vs early cyst distinction.

  • Diagnose and manage a dentigerous cyst, explaining its pathogenesis as fluid accumulation between reduced enamel epithelium and the enamel surface (crown inside the lumen, roots outside). High-yield: surrounds the crown of an impacted tooth (commonly lower 8s, tooth 47); treatment = enucleation + extraction of the associated tooth; alternative = marsupialisation ± orthodontic traction. Lower: cyst-fluid protein content, risk of ameloblastoma arising in the wall.

  • Recognise the odontogenic keratocyst (OKC), describe its unique clinicopathological features, and link it to Gorlin–Goltz syndrome. High-yield: peak incidence 10–30 yr; well-defined solitary or multilocular radiolucency; multiple OKCs = Gorlin–Goltz syndrome (with basal cell naevi, bifid ribs); recurrence up to 30%, driven by satellite/daughter cells and a friable lining; high-risk factors = large size, cortical perforation, daughter cysts. Lower: wide age range, mandibular body/ramus predilection, protein-rich fluid.

  • Recall the four histological hallmarks of OKC and explain why they distinguish it from other cysts and underpin its aggressive behaviour. High-yield: (1) uniform parakeratinised squamous epithelium 6–10 cells thick; (2) palisaded columnar/cuboidal basal cells; (3) corrugated luminal parakeratin; (4) no rete pegs — this combination is the named-histology exam target; the thin friable lining explains incomplete removal and recurrence. Lower: Ki-67 indices, PTCH1 mutation pathway in Gorlin–Goltz.

  • Apply adjunctive measures to reduce OKC recurrence after enucleation, justified by the biology of satellite-cell persistence. High-yield: peripheral ostectomy (removes margin epithelium), cryotherapy (liquid nitrogen), and Carnoy’s solution (chemical fixative) — all target the daughter-cell problem. Lower: freeze–thaw cycle specifics, Carnoy’s concentration/contact time.

  • Choose between enucleation and marsupialisation for jaw cysts, explaining the rationale and indications for each. High-yield: enucleation = complete one-stage removal — preferred for small/accessible cysts and OKC (allows adjunctive treatment); marsupialisation = “turns the cyst inside out” to decompress and shrink a large lesion before definitive removal — preferred when large, near vital structures (IAN, sinus), or in a growing patient. Lower: detailed surgical technique, obturator/plug fabrication.

Aggressive Cysts & Bone Lesions

  • Investigate a jaw bone lesion systematically and explain the role of each workup step in narrowing the differential. High-yield: clinical examination → vitality testing of adjacent teeth (distinguishes odontogenic from primary bone pathology) → OPG → CBCT/CT (cortical expansion, IAN/sinus proximity, contralateral comparison) → biopsy (definitive — clinical/radiological findings always need histopathological confirmation). Lower: MRI for soft-tissue components, FDG-PET for metabolic activity.

  • Build a differential for jaw bone lesions across the four major categories, recognising that many are systemic-disease manifestations not requiring local surgery. High-yield: benign fibro-osseous (cemento-osseous dysplasia, fibrous dysplasia, cherubism); metabolic (Paget disease, hyperparathyroidism); benign tumours/cysts (torus/osteoma, giant cell lesions — CGCG/ABC/traumatic bone cyst, peripheral giant cell granuloma); malignant (chondrosarcoma, Ewing sarcoma). Lower: odontogenic myxoma, cementoblastoma as additional sieve entries.

  • Differentiate monostotic from polyostotic fibrous dysplasia, describe its ground-glass radiographic appearance, and apply the correct management principle. High-yield: monostotic = most common fibro-osseous deformity of the head and neck; normal bone replaced by fibrous tissue; ground-glass pattern; overgrowth continues until skeletal maturity; management = cosmesis or relief of functional interference, not eradication. Lower: McCune–Albright syndrome, GNAS1 mutation mechanism.

  • Recognise the oral manifestations of hyperparathyroidism, including secondary hyperparathyroidism in renal failure, and apply the dental considerations for dialysis patients. High-yield: PTH dysregulation → hypercalcaemia; brown tumours and patchy bone loss are the jaw manifestations; secondary hyperparathyroidism = renal failure driving low calcium → parathyroid overactivity; avoid treatment on haemodialysis days (heparin → bleeding); bisphosphonate use → MRONJ awareness. Lower: calcitriol/hormone management in end-stage renal disease, Albright’s osteodystrophy.

  • Recognise central giant cell granuloma (CGCG), distinguish it from other giant cell lesions, and state its treatment. High-yield: intraosseous destructive lesion of multinucleated giant cells; cortical expansion, tooth mobility, root resorption; vitality testing mandatory to exclude periapical pathology; treatment = curettage; biopsy for definitive diagnosis. Lower: CGCG vs giant cell tumour of bone, medical alternatives (calcitonin, denosumab) for aggressive cases.

  • Distinguish aneurysmal bone cyst (ABC) from traumatic bone cyst, explaining that neither is a true cyst, and describe their key differences. High-yield: ABC = giant cell lesion, blood-filled spaces with fibrous septa and giant cells, peak 10–19 yr, posterior mandible, scallops between roots without resorption, curettage with ~20% recurrence; traumatic (haemorrhagic) bone cyst = empty cavity, asymptomatic, under age 20, no epithelial lining — surgical exploration induces a haematoma that heals spontaneously. Lower: primary vs secondary ABC, retreatment protocols.

  • Justify the conservative management of exostoses and tori, and apply the single indication for their surgical removal. High-yield: tori/exostoses are benign bony outgrowths needing no treatment unless they interfere with prosthetic rehabilitation or cause repeated trauma; removal is elective and function-driven. Lower: surgical technique for torus mandibularis vs palatinus, postoperative care.

  • Distinguish benign jaw lesions from aggressive/malignant lesions on radiographic and clinical grounds and recognise when features demand urgent workup. High-yield: benign = well-defined, corticated, displaces teeth, slow-growing, no cortical destruction; aggressive/malignant = ill-defined margins, root resorption, rapid growth, cortical perforation, unexplained mobility or numbness (IAN involvement) → urgent OPG + CBCT + biopsy; cemento-osseous dysplasia with vital adjacent teeth needs no treatment. Lower: imaging of specific malignant subtypes, permeative vs moth-eaten destruction patterns.

W3.4: Oral Cancer Resection and Reconstruction

  • Describe the epidemiology of oral and head and neck cancer in Australia and identify the predominant histological type, recognising that early diagnosis improves prognosis but most patients present late. High-yield: 7th most commonly diagnosed cancer in Australia; >5,000 new cases and >1,000 deaths in 2020; 90% of oral cancers are squamous cell carcinoma (SCC). Lower: global incidence comparisons, HPV-driven oropharyngeal SCC as a separate trend.

  • Identify the key clinical warning signs of oral cancer and apply them to triage any suspicious lesion, recognising that persistence beyond 2–3 weeks or a combination of features is the red-flag threshold. High-yield: non-healing ulcer >2–3 weeks, indurated heaped-up edges, erythroleukoplakia, localised unexplained tooth mobility, unexplained numbness, palpable neck lump, unexplained weight loss. Lower: ulcer morphology subtypes, trismus as a late sign.

  • Conduct a systematic intra- and extraoral cancer examination using a consistent routine, including bimanual palpation of cervical lymph nodes and thyroid, and targeted inspection of the highest-risk subsites. High-yield: lateral tongue, ventral tongue, floor of mouth, and lingual sulcus as highest-risk subsites; bimanual cervical node palpation; thyroid palpation on swallowing; OPG for “floating teeth” / localised unexplained bone loss. Lower: nasopharyngeal/parapharyngeal exam requiring endoscopy.

  • List and justify the investigations after a suspicious lesion is identified, including the preferred biopsy technique, specimen handling, and the role of advanced imaging in staging. High-yield: punch biopsy — depth > width, base detached, immediately into formalin; OPG and CXR first-line; CT/MRI for local invasion and nodes; PET for distant metastasis; endoscopy for nasopharynx/larynx. Lower: sentinel node biopsy, ultrasound-guided node FNA, contrast protocols.

  • Apply the TNM staging system, explaining how tumour size (T), regional nodal involvement (N), and distant metastasis (M) determine stage and drive treatment in the MDT setting. High-yield: TNM stage dictates surgery alone vs surgery + adjuvant therapy; node-positive disease and poorly differentiated histology are primary triggers for adjuvant radiotherapy; inadequate margins and failure to address the neck drive treatment failure. Lower: detailed T/N sub-classifications, AJCC 8th-edition changes for HPV-positive disease.

  • Describe the role of the Multidisciplinary Team (MDT) and articulate the dentist’s contributions before, during, and after treatment, including functional restoration and patient motivation. High-yield: core MDT — head and neck surgeon, radiation oncologist, medical oncologist, radiologist, pathologist, GP, dentist; the dentist evaluates and treats the mouth pre-, during-, and post-treatment; functional restoration of chewing, speech, and social eating; speech pathology if significant tongue is resected. Lower: social worker, physiotherapist, dietitian roles; nursing coordination.

  • Outline the treatment modalities for oral SCC and match each to its indication, distinguishing primary surgical management from radiotherapy- and chemotherapy-based strategies. High-yield: surgical ablation + neck dissection is the primary modality for oral cavity SCC; selective neck dissection preferred over radical (lower morbidity); adjuvant RTx for positive/close margins, nodal disease, poor differentiation; primary RTx ± chemotherapy for organ preservation in oropharyngeal cancers; chemotherapy in locally advanced disease. Lower: immunotherapy in recurrent/metastatic disease, brachytherapy.

  • Define the three surgical margin categories and explain their prognostic significance, recognising that close or positive margins independently worsen outcomes. High-yield: clear ≥5 mm; close 1–5 mm; involved (positive) <1 mm; survival improves with each additional millimetre of clear margin; close/positive margins cannot be fully compensated by adjuvant therapy. Lower: intraoperative frozen-section assessment, shrinkage-artefact effects on margin measurement.

  • Apply the 50–55 Gy radiation dose rule to pre-treatment dental planning, explain the rationale for dental clearance before radiotherapy, and outline the dentist’s long-term post-treatment responsibilities. High-yield: extract questionable-prognosis teeth in the radiation field if >55 Gy planned; conservative management acceptable <50 Gy if motivation is good; clearance ideally complete before RT (≥2 weeks, ideally 4–6 weeks); 3-monthly then 6-monthly recalls; Neutrafluor 5000 + fluoride varnish; xerostomia management; candidiasis monitoring; ORN is a lifelong risk — avoid extractions in irradiated bone. Lower: pancytopenia management during chemotherapy, saliva-substitute pharmacology.

  • Describe the reconstructive ladder for post-ablative defects and identify the named free-flap options by defect type and extent, recognising when vascularised bone is mandatory and the role of virtual surgical planning. High-yield: reconstructive ladder — secondary healing → primary closure → skin graft → local flap → regional flap → free flap; fibula osteocutaneous free flap for segmental mandibular defects (most common); radial forearm free flap for soft-tissue/marginal defects (Allen’s test first); scapular flap for chin/lip complex; segmental resection requires an osteocutaneous free flap; VSP + 3D-printed cutting guides improve accuracy. Lower: pedicled flap history (deltopectoral, pectoralis major), specific VSP software, anastomosis technique.

W4.1: Oral Radiography Workshop

  • Apply a systematic OPG review sequence as the foundational framework for every panoramic radiograph: begin with the clinical indication (which frames interpretation and medico-legal documentation), then artefact screening, then a fixed seven-region survey — dentoalveolar → maxilla/mandible → maxillary sinuses → TMJ condyles → soft tissues (calcifications) → other visible structures. High-yield: the seven-region fixed sequence (examiners test whether candidates skip regions); “address clinical concerns first” as the medico-legal anchor; use the contralateral unaffected side as an internal comparator. Lower: detailed normal-variant anatomy (stylohyoid calcification, enostoses, nutrient canals).

  • Recognise and name the common OPG artefacts so they are not misread as pathology: foreign objects (jewellery, dentures in situ), ghost images, positioning errors (chin down = exaggerated smile line/overlapping anteriors; chin up = flattened/reverse smile; head tilt = asymmetric condyles; head rotation = unilateral magnification), movement, soft-tissue errors (tongue not to palate → radiolucent band across roots), focal-trough errors, neck extension (cervical-spine ghost), and shoulder collision (cone-cut). High-yield: ghost image characteristics — opposite side, blurred, magnified, reversed (a classic spotter); chin-up vs chin-down effects on the smile line; tongue-to-palate failure as the most frequent positioning error. Lower: focal-trough geometry and layer-width physics.

  • Describe any radiographic lesion using the standard descriptors in sequence — location, number, symmetry, definition (corticated vs permeative margin), shape, size (referenced to anatomical/dental landmarks), homogeneity, internal architecture (unilocular/multilocular/septa), and effects on adjacent structures — applied to both lucencies and opacities. High-yield: effects on adjacent structures (displacement vs resorption vs scalloping vs sclerosis) as the descriptor that best separates benign-slow from aggressive lesions; a well-defined corticated border favours benign/cystic, a permeative margin favours malignancy/osteomyelitis. Lower: fine attenuation subclassification (ground-glass vs densely sclerotic) beyond naming.

  • Apply a radiology surgical sieve to generate a structured differential for any jaw lesion, working through the categories in order — artefactual → anatomical variant → anomaly → infective/inflammatory → cyst → hamartoma → benign odontogenic tumour → benign non-odontogenic tumour → idiopathic → fibro-osseous → malignancy → trauma → vascular → metabolic/systemic. High-yield: excluding artefact and anatomical variant before assigning pathology (a mark-scoring habit); fibro-osseous lesions and cysts as the most commonly tested mid-sieve categories; malignancy must always be explicitly considered and excluded. Lower: exhaustive named-lesion lists within each category.

  • Distinguish radiolucent, radiopaque, and mixed-density lesion patterns and use density as the first differential filter: lucencies suggest fluid-filled/inflammatory/destructive/cystic processes; opacities suggest mineralised tissue, reactive bone, or foreign material; mixed patterns suggest transitional lesions or aggressive lesions with both destruction and reactive bone. High-yield: cemento-osseous dysplasia maturation (radiolucent → mixed → opaque over time; a ~2-year follow-up OPG distinguishes active from maturing COD); periapical granuloma vs maturing COD as a classic case differential. Lower: CT Hounsfield-unit thresholds for tissue characterisation.

  • Identify the triggers that escalate investigation beyond an OPG and select the appropriate modality: CBCT for cortical integrity, bucco-lingual extent, and IAN-canal/sinus-floor proximity; MSCT for large-field skeletal/soft-tissue extension; MRI for soft-tissue characterisation; and routine radiologist consultation when findings exceed the clinician’s interpretive competence. High-yield: CBCT as the default step-up from OPG in oral surgery (cortical assessment and IAN proximity, as in M3M cases); CBCT does not replace MRI for soft-tissue lesions. Lower: CBCT voxel-size/field-of-view selection, MSCT protocol parameters.

  • Integrate the systematic review, lesion descriptors, surgical sieve, and escalation decision into a coherent case-presentation workflow, using the contralateral side as the primary internal comparator and documenting incidental findings. High-yield: the contralateral-comparator principle distinguishes systematic readers from lesion-spotters; documenting incidental findings is a medico-legal obligation. Lower: formal reporting templates and dictation conventions.

Graph View